Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Ino crawled time : 12:15 save search
INOVIO Expands Executive Leadership to Prepare for Commercial Operations
Published: 2021-11-05 (Crawled : 12:15) - inovio.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -1.65%
H: 0.0%
C: 0.0%
INO 4 d | $9.68 -5.1% -5.37% 350K
|
Health Technology
|
| O: -6.92%
H: 3.36%
C: -3.0%
commercialization
INOVIO Further Expands INNOVATE Phase 3 Trial for COVID-19 DNA Vaccine Candidate INO-4800 With Regulatory Authorization from India
Published: 2021-11-03 (Crawled : 12:15) - inovio.com
INO 4 d | $9.68 -5.1% -5.37% 350K
|
Health Technology
|
| O: 2.35%
H: 0.81%
C: 0.67%
covid india vaccine phase 3 trial ino-4800
INOVIO to Report Third Quarter 2021 Financial Results on November 9, 2021
Published: 2021-10-27 (Crawled : 12:15) - inovio.com
INO 4 d | $9.68 -5.1% -5.37% 350K
|
Health Technology
|
| O: -1.71%
H: 1.15%
C: -1.59%
financial results results
INOVIO to Present Three Posters at IDWeek 2021
Published: 2021-09-29 (Crawled : 12:15) - inovio.com
INO 4 d | $9.68 -5.1% -5.37% 350K
|
Health Technology
|
| O: 0.95%
H: 2.61%
C: -2.55%
INOVIO Receives Regulatory Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800, in Mexico
Published: 2021-09-22 (Crawled : 12:15) - inovio.com
INO 4 d | $9.68 -5.1% -5.37% 350K
|
Health Technology
|
| O: 0.25%
H: 0.76%
C: -1.14%
covid vaccine phase 3 trial authorized ino-4800
INOVIO Receives Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800
Published: 2021-08-26 (Crawled : 12:15) - inovio.com
INO 4 d | $9.68 -5.1% -5.37% 350K
|
Health Technology
|
| O: 4.86%
H: 8.36%
C: -1.69%
covid vaccine phase 3 trial authorized ino-4800
INOVIO Expands Partnership with Advaccine to Conduct Global Phase 3 Efficacy Trial of COVID-19 DNA Vaccine Candidate, INO-4800
Published: 2021-06-08 (Crawled : 12:15) - inovio.com
INO 4 d | $9.68 -5.1% -5.37% 350K
|
Health Technology
|
| O: 2.49%
H: 0.46%
C: -0.69%
covid partnership vaccine phase 3 trial ino-4800
INOVIO to Report First Quarter 2021 Financial Results on May 10, 2021
Published: 2021-04-27 (Crawled : 12:15) - inovio.com
INO 4 d | $9.68 -5.1% -5.37% 350K
|
Health Technology
|
| O: 1.73%
H: 3.11%
C: 1.41%
financial results results
INOVIO Planning for ex-US Global Phase 3 Trial for INO-4800
Published: 2021-04-23 (Crawled : 12:15) - inovio.com
INO 4 d | $9.68 -5.1% -5.37% 350K
|
Health Technology
|
| O: -27.71%
H: 6.67%
C: 3.79%
phase 3 trial ino-4800
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.